Asthma exacerbations during long term β agonist use: influence of β2 adrenoceptor polymorphism
- D Robin Taylora,
- Jeffrey M Drazend,
- G Peter Herbisonb,
- Chandra N Yandavad,
- Robert J Hancoxa,
- G Ian Townc
- aDepartment of Medicine, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand, bDepartment of Preventive and Social Medicine, cCanterbury Respiratory Research Group, Christchurch School of Medicine, University of Otago, Christchurch, New Zealand, dPulmonary and Critical Care Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA
- Dr D R Taylor email:robin.taylor{at}stonebow.otago.ac.nz
- Received 6 December 1999
- Revision requested 10 February 2000
- Revised 4 April 2000
- Accepted 26 May 2000
Abstract
BACKGROUND Polymorphisms of the β2 adrenoceptor influence receptor function in vitro and asthma phenotypes in vivo. However, their importance in determining responses to inhaled β agonist treatment has not been clearly defined.
METHODS In a retrospective analysis of previously published data we have examined relationships between polymorphisms at codons 16 and 27 of the β2 adrenoceptor and clinical outcomes in a randomised, placebo controlled, crossover trial of regularly scheduled salbutamol and salmeterol in 115 patients with mild to moderate asthma. Genotyping was obtained for positions 16 and 27 in 108 and 107 patients, respectively. For position 16, 17 patients (16%) were homozygous Arg-Arg, 40 (37%) were heterozygous Arg-Gly, and 51 (47%) were homozygous Gly-Gly.
RESULTS Within the homozygous Arg-16 group major exacerbations were more frequent during salbutamol treatment than with placebo (1.91 (95% CI 1.07 to 3.12) per year versus 0.81 (95% CI 0.28 to 1.66) per year; p = 0.005). No significant treatment related differences occurred for heterozygous Arg-Gly patients (salbutamol 0.11 (95% CI 0.01 to 0.40), placebo 0.54 (95% CI 0.26 to 1.00) exacerbations per year) or homozygous Gly-16 patients (salbutamol 0.38 (95% CI 0.17 to 0.73), placebo 0.30 (95% CI 0.12 to 0.61) exacerbations per year). No adverse changes occurred for any position 16 subgroup with salmeterol. There was no significant relationship between position 27 genotypes and treatment related outcomes.
CONCLUSION Homozygous Arg-16 patients are susceptible to clinically important increases in asthma exacerbations during chronic dosing with the short acting β2 agonist salbutamol.
Footnotes
-
Dr Hancox was a Glaxo Wellcome Research Fellow.
